Review Article
Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative
Marius Rademaker,
Karen Agnew,
Megan Andrews, Christopher Baker,
Peter Foley,
Kurt Gebauer,
Monisha Gupta,
Diana M. Rubel,
Colin Somerville,
John Sullivan,
Li-Chuen Wong,
Corresponding Author
Marius Rademaker
Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand
Correspondence: Marius Rademaker, Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand. Email: [email protected]Search for more papers by this authorKaren Agnew
Dermatology Department, Greenlane Clinical Centre, Auckland, New Zealand
Starship Children's Hospital, Auckland, New Zealand
Search for more papers by this authorChristopher Baker
St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Skin & Cancer Foundation Inc., Carlton, Victoria, Australia
Search for more papers by this authorPeter Foley
St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Skin & Cancer Foundation Inc., Carlton, Victoria, Australia
Search for more papers by this authorKurt Gebauer
University of Western Australia, Perth, Western Australia, Australia
Probity Medical Research, Freemantle, Western Australia, Australia
Search for more papers by this authorMonisha Gupta
Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia
The Skin Hospital, Darlinghurst, New South Wales, Australia
University of New South Wales, Sydney, New South Wales, Australia
Search for more papers by this authorDiana M. Rubel
Woden Dermatology, Phillip, Australian Capital Territory, Australia
Australian National University, Canberra, Australian Capital Territory, Australia
Search for more papers by this authorColin Somerville
The Allergy West Clinic - Immunology, Perth, Western Australia, Australia
Search for more papers by this authorJohn Sullivan
Kingsway Dermatology, Miranda, New South Wales, Australia
Search for more papers by this authorLi-Chuen Wong
The Children's Hospital at Westmead, Sydney, New South Wales, Australia
Search for more papers by this authorMarius Rademaker,
Karen Agnew,
Megan Andrews, Christopher Baker,
Peter Foley,
Kurt Gebauer,
Monisha Gupta,
Diana M. Rubel,
Colin Somerville,
John Sullivan,
Li-Chuen Wong,
Corresponding Author
Marius Rademaker
Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand
Correspondence: Marius Rademaker, Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand. Email: [email protected]Search for more papers by this authorKaren Agnew
Dermatology Department, Greenlane Clinical Centre, Auckland, New Zealand
Starship Children's Hospital, Auckland, New Zealand
Search for more papers by this authorChristopher Baker
St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Skin & Cancer Foundation Inc., Carlton, Victoria, Australia
Search for more papers by this authorPeter Foley
St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Skin & Cancer Foundation Inc., Carlton, Victoria, Australia
Search for more papers by this authorKurt Gebauer
University of Western Australia, Perth, Western Australia, Australia
Probity Medical Research, Freemantle, Western Australia, Australia
Search for more papers by this authorMonisha Gupta
Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia
The Skin Hospital, Darlinghurst, New South Wales, Australia
University of New South Wales, Sydney, New South Wales, Australia
Search for more papers by this authorDiana M. Rubel
Woden Dermatology, Phillip, Australian Capital Territory, Australia
Australian National University, Canberra, Australian Capital Territory, Australia
Search for more papers by this authorColin Somerville
The Allergy West Clinic - Immunology, Perth, Western Australia, Australia
Search for more papers by this authorJohn Sullivan
Kingsway Dermatology, Miranda, New South Wales, Australia
Search for more papers by this authorLi-Chuen Wong
The Children's Hospital at Westmead, Sydney, New South Wales, Australia
Search for more papers by this authorMarius Rademaker, DM, FRCP. Karen Agnew, FRACP. Megan Andrews, FACD. Christopher Baker, FACD. Peter Foley, MD, FACD. Kurt Gebauer, FACD. Monisha Gupta, FACD. Diana M Rubel, FACD. Colin Somerville, FRACP. John Sullivan, FACD. Li-Chuen Wong, FACD.
Conflicts of Interest: Rademaker, Agnew, Andrews, Gupta, Somerville, Sullivan: None; Baker: Clinical Investigator, speaker and/or advisory board: AbbVie, Janssen, Novartis, Pfizer; Foley: Consultant, investigator, speaker and/or advisor for and/or received travel grants: 3M/iNova/Valeant, Abbott/AbbVie, Amgen, Biogen Idec, BMS, Boehringer Ingelheim, Celgene, Celtaxsys, Cutanea, Dermira, Eli Lilly, Galderma, GSK/Stiefel, Janssen, LEO/Peplin, Novartis, Regeneron, Sanofi Genzyme, Schering-Plough/MSD, Sun Pharma, UCB, and Wyeth/Pfizer; Gebauer: Clinical investigator and/or Advisory Board: AbbVie, Celgene, Janseen, Eli Lilly; Rubel: Clinical Investigator and/or Advisory Board: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Sun Pharma; Wong: Advisory Board: Pfizer.
Abstract
With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.
Supporting Information
| Filename | Description |
|---|---|
| ajd13141-sup-0001-AppendixS1.docxWord document, 22.6 KB | Appendix S1. Clinical scenarios. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr. Dermatol. 2019; 36: 36–65.
- 2Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin. Dermatol. 2018; 36: 648–52.
- 3Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J. Eur. Acad. Dermatol. Venereol. 2018; 32: 657–82.
- 4Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J. Eur. Acad. Dermatol. Venereol. 2018; 32: 850–78.
- 5de María Díaz Granados L, Quijano MA, Ramírez PA et al. Quality assessment of atopic dermatitis clinical practice guidelines in ≤ 18 years. Arch. Dermatol. Res. 2018; 310: 29–37.
- 6Simpson EL, Bruin-Weller M, Flohr C et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J. Am. Acad. Dermatol. 2017; 77: 623–33.
- 7Armstrong A, Huang A, Wang L et al. Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. J. Am. Acad. Dermatol. 2017; 76 (Suppl 1): AB215.
- 8Armstrong A, Moon R, Bell D et al. Real-world disease burden in US adults with moderate-to-severe atopic dermatitis eligible for treatment with systemic immunosuppressants. J. Am. Acad. Dermatol. 2017; 76 (Suppl 1): AB215.
- 9Lynde CW, Bourcier M, Gooderham M et al. A treatment algorithm for moderate to severe atopic dermatitis in adults. J. Cutan. Med. Surg. 2018; 22: 78–83.
- 10Totri CR, Eichenfield LF, Logan K et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J. Am. Acad. Dermatol. 2017; 76: 281–5.
- 11Drucker AM, Eyerich K, de Bruin-Weller MS et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br. J. Dermatol. 2018; 178: 768–75.
- 12Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905–17.
- 13Sonenthal KR, Grammer LC, Patterson R. Do some patients with atopic dermatitis require long-term oral steroid therapy? J. Allergy Clin. Immunol. 1993; 91: 971–3.
- 14Heddle RJ, Soothill JF, Bulpitt CJ et al. Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomized controlled trial. Br. Med. J. (Clin Res Ed) 1984; 289: 651–4.
- 15Aylett SE, Atherton DJ, Preece MA. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone diproprionate. Acta Derm. Venereol. (Stockh.) 1992; 1992: 123–5.
- 16La Rosa M, Musarra I, Ranno C et al. A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr. Ther. Res. 1995; 56: 720–6.
- 17Schmitt J, Schakel K, Folster-Holst R et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br. J. Dermatol. 2010; 162: 661–8.
- 18Steinke S, Langenbruch A, St€ander S et al. Therapeutic benefits in atopic dermatitis from patients’ perspective: results of the German national health care study ‘Atopic Health’. Dermatology 2014; 228: 350–9.
- 19Stroud GM, Miller RE, Kozikoski ES. Oral versus intramuscular methylprednisolone. A double-blind study. Arch. Dermatol. 1963; 1963: 710–4.
10.1001/archderm.1963.01590180038008 Google Scholar
- 20Reddy S, Ananthakrishnan S, Garg A. A prospective observational study evaluating hypothalamic-pituitary-adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatologic disease. J. Am. Acad. Dermatol. 2013; 69: 226–31.
- 21Galli E, Chini L, Moschese V et al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr. 1994; 83: 315–7.
- 22Khan SA, Smith AF. Tetracosactrin-depot therapy in dermatology. Br. J. Dermatol. 1970; 82: 389–96.
- 23Munro DD. Corticotrophin and tetracosactrin depot—self administered for the treatment of eczema. Br. J. Dermatol. 1976; 94 (Suppl 12): 135–8.
- 24Broersen LH, Pereira AM, Jørgensen JO et al. Adrenal insufficiency in corticosteroid use: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100: 2171–80.
- 25Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am. J. Med. Genet. 1999; 86: 242–4.
10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 26Rayburn WF. Glucocorticoid therapy for rheumatic diseases: maternal, fetal, and breast-feeding considerations. Am. J. Reprod. Immunol. 1992; 28: 138–40.
- 27Rademaker M, Gupta M, Andrews M et al. The Australasian Psoriasis Collaboration view on Methotrexate for psoriasis in the Australasian setting. Australas. J. Dermatol. 2017; 58: 166–70.
- 28Roekevisch E, Spuls PI, Kuester D et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 2014; 133: 429–38.
- 29Weatherhead SC, Wahie S, Reynolds NJ et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br. J. Dermatol. 2007; 156: 346–51.
- 30Schram ME, Roekevisch E, Leeflang MM et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J. Allergy Clin. Immunol. 2011; 128: 353–9.
- 31Roekevisch E, Schram ME, Leeflang MM et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. J. Allergy Clin. Immunol. 2018; 141: 825–7.e10.
- 32Goujon C, Viguier M, Staumont-Sallé D et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized non inferiority trial. J. Allergy Clin. Immunol. Pract. 2018; 6: 562–9.
- 33Law Ping Man S, Bouzillé G, Beneton N et al. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J. Eur. Acad. Dermatol. Venereol. 2018; 32: 1327–35.
- 34Politiek K, van der Schaft J, Coenraads PJ et al. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br. J. Dermatol. 2016; 174: 201–3.
- 35Delcasso B, Goujon C, Hacard F et al. Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis. Eur. J. Dermatol. 2018; 28: 266–7.
- 36Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br. J. Dermatol. 2000; 142: 52–8.
- 37Granlund H, Erkko P, Sinisalo M et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br. J. Dermatol. 1995; 132: 106–12.
- 38Sidbury R, Davis DM, Cohen DE et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J. Am. Acad. Dermatol. 2014; 71: 327–49.
- 39Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opin. Drug Saf. 2014; 13: 1591–9.
- 40Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J. Dermatolog. Treat. 2012; 23: 290–304.
- 41Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomized controlled trial. Lancet 2006; 367: 839–46.
- 42Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br. J. Dermatol. 2002; 147: 324–30.
- 43Haeck IM, Knol MJ, Ten Berge O et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J. Am. Acad. Dermatol. 2011; 64: 1074–84.
- 44Dréno B, Araviiskaia E, Berardesca E et al. Microbiome in healthy skin, update for dermatologists. J. Eur. Acad. Dermatol. Venereol. 2016; 30: 2038–47.
- 45Thomas CL, Fernández-Peñas P. The microbiome and atopic eczema: more than skin deep. Australas. J. Dermatol. 2017; 58: 18–24.
- 46Hepburn L, Hijnen DJ, Sellman BR et al. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. Br. J. Dermatol. 2017; 177: 63–71.
- 47Ong PY. Recurrent MRSA skin infections in atopic dermatitis. J. Allergy Clin. Immunol. Pract. 2014; 2: 396–9.
- 48Hsu CJ, Wang LF. Emerging treatment of atopic dermatitis. Clin. Rev. Allergy Immunol. 2007; 33: 199–203.
- 49Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br. J. Dermatol. 2004; 150: 1182–5.
- 50Chin WK, Lee SWH. A systematic review on the off-label use of montelukast in atopic dermatitis treatment. Int. J. Clin. Pharm. 2018; 40: 963–76.
- 51Cavero-Carbonell C, Vinkel-Hansen A, Rabanque-Hernández MJ et al. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res. 2017; 109: 452–9.
- 52Keaney TC, Bhutani T, Sivanesan P et al. Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. J. Am. Acad. Dermatol. 2012; 67: 636–41.
- 53van der Schaft J, van Schaik RH, van Zuilen AD et al. First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. J. Dermatol. Sci. 2016; 81: 66–8.
- 54Lee FJ, Frankum BS, Katelaris CH. Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series. Australas. J. Dermatol. 2012; 53: 295–7.
- 55Schroer B, Lockey R. Oral tacrolimus for severe recalcitrant atopic eczema. J. Allergy Clin. Immunol. 2003; 111: 1409–10.
- 56Jee SJ, Kim JH, Baek HS et al. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol. Res. 2011; 3: 89–95.
- 57Turner PJ, Kakakios A, Wong LC et al. Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr. Dermatol. 2012; 29: 177–81.
- 58Jolles S, Sewell C, Webster D et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm. Venereol. 2003; 83: 433–7.
- 59Nahm DH, Kim ME, Cho SM. Effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis. Dermatology 2015; 231: 145–51.
- 60Hanifin JM, Schneider LC, Leung DY et al. Recombinant interferon gamma therapy for atopic dermatitis. J. Am. Acad. Dermatol. 1993; 28: 189–97.
- 61Jang IG, Yang JK, Lee HJ et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 2000; 42: 1033–40.
- 62Czarnowicki T, Gonzalez J, Shemer A et al. Severe atopic dermatitis is characterized by selective expansion of circulating Th2/Tc2 and Th22/Tc22 but not Th17/Tc17 cells within the skin homing T cell population. J. Allergy Clin. Immunol. 2015; 136: 104–15.
- 63Ruzicka T, Lynde CW, Jemec GB et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br. J. Dermatol. 2008; 158: 808–17.
- 64Grahovac M, Molin S, Prinz JC et al. Treatment of atopic eczema with oral alitretinoin. Br. J. Dermatol. 2010; 162: 217–8.
- 65Schmitt J, Abraham S, Trautmann F et al. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany. J. Dtsch. Dermatol. Ges. 2017; 15: 49–59.
- 66Huang CM, Lara-Corrales I, Pope E. Effects of Vitamin D levels and supplementation on atopic dermatitis: a systematic review. Paediatr. Dermatol. 2018; 35: 754–60.
- 67Kim G, Bae JH. Vitamin D and atopic dermatitis: a systematic review and meta-analysis. Nutrition 2016; 32: 913–20.
- 68Hyppönen E, Sovio U, Wjst M et al. Infant Vitamin D supplementation and allergic conditions in adulthood: northern Finland birth cohort 1996. Ann. N. Y. Acad. Sci. 2004; 1037: 84–95.
- 69Jaffary F, Faghihi G, Mokhtarian A et al. Effects of oral vitamin E on treatment of atopic dermatitis: a randomised trial. J. Res. Med. Sci. 2015; 20: 1053–7.
- 70Bath-Hextall FJ, Jenkinson C, Humphreys R et al. Dietary supplements for established atopic eczema. Cochrane Database Syst. Rev. 2012; (2): CD005205.
- 71Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr. Opin. Allergy Clin. Immunol. 2018; 18: 432–7.
- 72Vakharia P, Silverberg J. New therapies for atopic dermatitis: additional treatment classes. J. Am. Acad. Dermatol. 2018; 78: S76–83.
- 73Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 2016; 375: 2335–48.
- 74Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287–303.
- 75Wollenberg A, Howell MD, Guttman-Yassky E et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J. Allergy Clin. Immunol. 2019; 143: 135–41.
- 76Simpson EL, Flohr C, Eichenfield LF et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J. Am. Acad. Dermatol. 2018; 78: 863–71.
- 77Ruzicka T, Hanifin JM, Furue M et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N. Engl. J. Med. 2017; 376: 826–35.
- 78Holm JG, Agner T, Sand C et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int. J. Dermatol. 2017; 56: 18–26.
- 79Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update. Exp. Ther. Med. 2019; 17: 1061–7.
- 80Oldhoff JM, Darsow U, Werfel T et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693–6.
- 81Simon D, Hösli S, Kostylina G et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol. 2008; 121: 122–8.
- 82Jacobi A, Antoni C, Manger B et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2005; 52: 522–6.
- 83Khattri S, Brunner PM, Garcet S et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp. Dermatol. 2017; 26: 28–35.
- 84Simpson EL, Parnes JR, She D et al. Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J. Am. Acad. Dermatol. 2019; 80: 1013–21.
- 85Cotter DG, Schairer D, Eichenfield L et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J. Drugs Dermatol. 2012; 11: 341–6.
- 86Schwartz DM, Bonelli M, Gadina M et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 2016; 12: 25–36.
- 87Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J. Am. Acad. Dermatol. 2018; 78 (3 Suppl 1): S53–62.
- 88Guttman-Yassky E, Silverberg JI, Nemoto O et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J. Am. Acad. Dermatol. 2018; 80: 913–21.e9.
- 89Guttman-Yassky E, Anderson J, Pangan A et al. Primary results from a phase 2b, randomized, placebo-controlled trial of upadacitinib for patients with atopic dermatitis [abstract]. American Academy of Dermatology Annual Meeting; Feb 16–20; San Diego 2018.
- 90Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J. Am. Acad. Dermatol. 2015; 73: 395–9.
- 91Schram ME, Spuls PI, Leeflang MM et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106.
Citing Literature
